SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Center for Disease Control and Prevention. Available at http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/ (last accessed 14 October 2009).
  • 2
    Poirier P, Eckel RH. Cardiovascular consequences of obesity. Drug Discov Today Ther Strat 2008; 5: 4551.
  • 3
    Mittendorfer B, Peterson LR. Cardiovascular consequences of obesity and targets for treatment. Drug Discov Today Ther Strat 2008; 5: 5361.
  • 4
    Calle EE, Thun MJ, Petrelli JM, Rogriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097105.
  • 5
    Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Affairs 2003; W3: 21926.
  • 6
    Daniels SR. The consequences of childhood overweight and obesity. Future Child 2006; 16: 4767.
  • 7
    Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer X, Ronnett GV, Tan TMM, Weigle DS. The obesity epidemic: pharmacological challenges. Mol Interv 2008; 8: 8298.
  • 8
    Blundell JE, Levin F, King NA, Barkeling B, Gustafson T, Hellstrom PM, Holst JJ, Naslund E. Overconsumption and obesity: peptides and susceptibility to weight gain. Regul Pept 2008; 149: 328.
  • 9
    Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 66171.
  • 10
    Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93: S3750.
  • 11
    Abizaid A, Horvath TL. Brain circuits regulating energy homeostasis. Regul Pept 2008; 149: 310.
  • 12
    Hameed S, Dhillo WS, Bloom SR. Gut hormones and appetite control. Oral Dis 2009; 15: 1826.
  • 13
    Knecht S, Ellger T, Levine JA. Obesity in neurobiology. Prog Neurobiol 2008; 84: 85103.
  • 14
    Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 15868.
  • 15
    Wikberg JES, Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat Rev Drug Discov 2008; 7: 30723.
  • 16
    Adamantidis A, De Lecea L. Sleep and metabolism: shared circuits, new connections. Trends Endocrinol Metab 2008; 19: 36270.
  • 17
    Adan RAH, Vanderschuren LJMJ, La Fleur SE. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008; 29: 20817.
  • 18
    Moran TH, Aja S, Ladenheim EE. Leptin modulation of peripheral controls of meal size. Physiol Behav 2006; 89: 5116.
  • 19
    Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. Cell 2007; 129: 25162.
  • 20
    Benoit SC, Tracy AL, Davis JF, Choi D, Clegg DJ. Novel functions of orexigenic hypothalamic peptides: from genes to behavior. Nutrition 2008; 24: 8437.
  • 21
    Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59: 15184.
  • 22
    Clapham JC, Arch JRS, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001; 89: 81121.
  • 23
    Clifton PG, Kennett GA. Monoamine receptors in the regulation of feeding behaviour and energy balance. CNS Neurol Disord Drug Targets 2006; 5: 293312.
  • 24
    Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 2007; 32: 82234.
  • 25
    Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP. Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 2000; 397: 93102.
  • 26
    Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 11949.
  • 27
    Greenapple R. Available at http://www.fiercepharma.com/special-reports/can-obesity-treatment-be-cost-effective (last accessed 15 October 2009).
  • 28
    Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 185960.
  • 29
    Company information. Available at http://www.medicalnewstoday.com/articles/83621.php (last accessed 15 October 2009).
  • 30
    Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, Anderson JG, Heisler LK, Zigman JM, Lowell BB, Elmquist JK. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008; 60: 5829.
  • 31
    Qiu J, Xue C, Bosch MA, Murphy JG, Fan W, Rønnekleiv OK, Kelly MA. Serotonin 5-hydroxytryptamine2c receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy homeostasis in females. Mol Pharmacol 2007; 72: 88596.
  • 32
    Heisler LK, Jobst EE, Sutton GM, Zhou L, Borok E, Thornton-Jones Z, Liu HY, Zigman JM, Balthasar N, Kishi T, Lee CE, Aschkenasi CJ, Zhang C-Y, Yu J, Boss O, Mountjoy KG, Clifton PG, Lowell BB, Friedman JM, Horvath T, Butler AA, Elmquist JK, Cowley MA. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006; 51: 23949.
  • 33
    Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, Oksanen LJ, Thornton-Jones ZD, Clifton PG, Yueh C-Y, Evans ML, McCrimmon RJ, Elmquist JK, Butler AA, Heisler LK. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007; 6: 398405.
  • 34
    Company information. Available at http://www.arenapharm.com (last accessed 15 October 2009).
  • 35
    Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008; 117: 20731.
  • 36
    Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001; 41: 2109.
  • 37
    Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R, Holenz J, Heal D, Buschmann H, Pauwels PJ. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006; 148: 97383.
  • 38
    Akbas F, Gasteyger C, Sjödin A, Astrup A, Larsen TM. A critical review of the cannabinoid receptor as a drug target for obesity management.Obes Rev 2008; 10: 5867.
  • 39
    Di Marzo V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today 2008; 13: 102641.
  • 40
    Trillou CR, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand J-P, Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R34553.
  • 41
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006; 295: 76175.
  • 42
    Plieth J. Obesity: what next after the CB1 antagonists' failure? Scrip 2008; 7 November 2008, 447.
  • 43
    Company information. Available at http://www.orexigen.com (last accessed 15 October 2009).
  • 44
    Company information. Available at http://www.vivus.com (last accessed 15 October 2009).
  • 45
    Mashiko S, Ishihara A, Iwaasa H, Sano H, Ito J, Gomori A, Oda Z, Moriya R, Matsushita H, Jitsuoka M, Okamoto O, MacNeil DJ, Van der Ploeg LHT, Fukami T, Kanatani A. A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Mol Pharmacol 2007; 71: 6028.
  • 46
    Levens NR, Della-Zuana O. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs. Curr Opin Investig Drugs 2003; 4: 1198204.
  • 47
    Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohorquez SM, Eng W, Langstrom B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006; 4: 27582.
  • 48
    Company information. Available at http://www.shionogiusa.com/media.html (last accessed 15 October 2009).
  • 49
    Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins. Pharmacological Res 2008; 59: 1347.
  • 50
    Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, Pfluger PT, Castaneda TR, Neschen S, Hofmann SM, Howles PN, Morgan DA, Benoit SC, Szanto I, Schrott B, Schürmann A, Joost H-G, Hammond C, Hui DY, Woods SC, Rahmouni K, Butler AA, Farooqi IS, O'Rahilly S, Rohner-Jeanrenaud F, Tschöp MH. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 2007; 117: 347588.
  • 51
    Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists. Life Sci 2007; 81: 42340.
  • 52
    Mendez-Andino J, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007; 12: 9729.
  • 53
    Kowalski TJ, Farley C, Cohen-Williams ME, Varty G, Spar BD. Melanin concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size. Eur J Pharmacol 2004; 497: 417.
  • 54
    Shearman LP, Camacho RE, Sloan Stribling D, Zhou D, Bednarek MA, Hreniuk DL, Feighner SD, Tan CP, Howard AD, Van der Ploeg LH, MacIntyre DE, Hickey GJ, Alison M, Strack AM. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur J Pharmacol 2003; 475: 3747.
  • 55
    Sargent B, Surman M, Freeman E, Grabowski J, Jiang X-W, Jiang G, Hadden M, Luche M, Khmelnitsky Y, Lindsay J, Mozhaeva L, Zaremba J, Viggers J, Vickers S, Goddard S, Cheetham S, Guzzo P. Comparative pharmacology of AMR-MCH-1 and AMR-MCH-2, MCH1 receptor antagonists for the treatment of obesity. Proceedings of the British Pharmacological Society (2008) Available at http://www.pA2online.org/abstracts/Vol6Issue4abst114P.pdf (last accessed 15 October 2009).
  • 56
    Company information. Available at http://www.neurogen.com/index.php?option=com_content&view=article&id=63&Itemid=78&p=irol-news (last accessed 15 October 2009).